AT-Patch (ATP-C130/ATP-C70) vs VX1

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AT-Patch (ATP-C130/ATP-C70)

by ATsens Co.

VX1

by Volta Medical

AI Verdict

These tools are adjacent rather than direct competitors, as they serve distinct purposes within cardiology. AT-Patch focuses on long-term, continuous ECG monitoring for arrhythmia detection, ideal for diagnosis and remote patient management. In contrast, VX1 is an AI-powered software designed to assist electrophysiologists in real-time during complex ablation procedures for atrial fibrillation and tachycardia.

Choose AT-Patch (ATP-C130/ATP-C70) if…

Choose AT-Patch if you require extended, non-invasive outpatient monitoring for arrhythmia detection and diagnosis. This wearable ECG monitor offers up to 14 days of continuous, high-accuracy cardiac data collection with AI-powered analysis, ideal for patients needing remote, comfortable, and shower-proof monitoring for intermittent symptoms. It's best suited for identifying elusive arrhythmias that may not be captured during shorter in-clinic visits.

View AT-Patch (ATP-C130/ATP-C70) →

Choose VX1 if…

Choose VX1 if you are an electrophysiologist performing atrial fibrillation or atrial tachycardia ablation procedures and need real-time, AI-guided assistance. This software integrates with existing EP lab systems to identify dispersed electrograms, aiming to enhance procedural efficacy and standardize outcomes. It is specifically designed to provide critical insights during complex interventional cardiology procedures.

View VX1 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AT-Patch (ATP-C130/ATP-C70)	VX1
Pricing	N/a	Contact for pricing
Deployment	Wearable device for patients; analysis software deployed on-premise at medical institutions.	Software integrated with existing electrophysiology (EP) lab mapping and recording systems.
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AT-Patch (ATP-C130/ATP-C70)

AT-Patch focuses on patient comfort and ease of use with its compact, shower-proof design and smartphone app for live viewing, making it highly accessible for continuous monitoring. While VX1 aids clinicians in a complex procedural setting, AT-Patch's patient-facing design and simple operation for extended periods give it an edge in overall usability.

Clinical Value

VX1

VX1 provides real-time AI-guided assistance during complex cardiac ablation procedures, aiming to reduce variability and standardize outcomes, directly impacting the success of an invasive intervention. While AT-Patch offers valuable long-term diagnostic monitoring, VX1's role in improving high-stakes procedural efficacy represents a distinct and potentially higher level of clinical impact.

Pricing & Value

Tie

Neither tool provides publicly available pricing information, making it impossible to conduct a comparative analysis of their cost-effectiveness or overall value proposition. Without transparent pricing, a definitive winner cannot be determined for this dimension.

Enterprise Readiness

VX1

VX1 explicitly highlights its compatibility with most existing EP recording, 3D navigation systems, and mapping catheters, demonstrating a strong focus on seamless integration into complex hospital environments. While AT-Patch offers on-premise software, VX1's detailed compatibility claims suggest a more robust consideration for enterprise deployment within its specialized niche.

Innovation

VX1

VX1's application of AI for real-time guidance during complex atrial fibrillation and tachycardia ablation procedures represents a significant innovation in interventional cardiology. This real-time, procedural assistance pushes the boundaries of AI in high-stakes clinical settings, offering a more novel approach compared to AT-Patch's advanced but more established use of AI for diagnostic monitoring.

Support & Docs

Tie

The provided structured facts and general web searches do not offer specific details regarding the availability, quality, or scope of support and documentation for either AT-Patch or VX1. Therefore, it is not possible to differentiate between the two tools in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AT-Patch (ATP-C130/ATP-C70)	VX1
Product Name	AT-Patch (ATP-C130/ATP-C70)	VX1
Company	ATsens Co.	Volta Medical
Primary Function	Wearable ECG monitor for continuous cardiac monitoring with AI-powered analysis for arrhythmia detection.	AI software assisting cardiac electrophysiologists in real-time identification of dispersed electrograms during ablation procedures.
Categories	Cardiology AI, Wearables & Remote Monitoring (RPM)	Cardiology AI, Surgical AI
Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology
AI/ML Capabilities	Integrated AI-powered analysis software for enhanced arrhythmia detection; AT-Report software with AI/machine learning algorithms for ECG analysis.	AI-guided real-time identification of dispersed electrograms (EGMs); analyzes 3D anatomical and electrical maps of human atria.
Key Monitoring/Procedure Aspect	Up to 14 days of continuous ECG monitoring.	Assists cardiologists during AFib and atrial tachycardia ablation procedures.

Videos

Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and VX1.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the distinct clinical applications of the AT-Patch and VX1?

The AT-Patch is an FDA-cleared wearable ECG monitor designed for continuous cardiac monitoring for up to 14 days, primarily for arrhythmia detection in patients. In contrast, Volta Medical's VX1 is FDA-clecleared AI software that assists cardiac electrophysiologists in real-time during atrial fibrillation and atrial tachycardia ablation procedures by identifying dispersed electrograms.

How do these tools integrate into existing clinical workflows and infrastructure?

The AT-Patch involves a wearable device for patients, with its analysis software deployed on-premise at medical institutions. The VX1 is software that integrates with existing electrophysiology lab mapping and recording systems, meaning it works within the EP lab's current setup.

What specific types of patient data does each tool utilize for its AI analysis?

The AT-Patch's AI analyzes continuous ECG signals acquired from the wearable patch for arrhythmia detection. The VX1's AI analyzes 3D anatomical and electrical maps of human atria and electrograms in real-time to identify dispersed electrograms during ablation procedures.

What are the key differences in the AI's function and output for each tool?

The AT-Patch's AI provides analysis for enhanced arrhythmia detection from long-term ECG data, aiding in the diagnosis of heart conditions. The VX1's AI offers real-time, AI-guided identification of specific abnormal electrograms during ablation, designed to reduce inter-operator variability and standardize outcomes.

Which medical specialties are primarily targeted by each tool?

The AT-Patch is designed for use across Cardiology, Family Medicine, and Internal Medicine due to its continuous cardiac monitoring capabilities. The VX1 is specifically targeted at Cardiology, particularly assisting cardiac electrophysiologists during AFib and atrial tachycardia ablation procedures.